A CITF-funded study, published in Open Forum Infectious Diseases, reported that individuals 90 years and older had higher levels of infection-acquired SARS-CoV-2 antibodies and more efficient antibody neutralization than younger groups (under 65, and 65-89), but their antibodies decayed at a faster rate.